Basic information
- CAS
10381-75-6- Standard SMILES
Cn1c(=O)c2[nH]c(Br)nc2n(C)c1=O- InChIKey
SKTFQHRVFFOHTQ-UHFFFAOYSA-N- Molecular formula
- C7H7BrN4O2
- Average molar mass
- 259.06 g/mol
- Monoisotopic mass
- 257.97524
Names & identifiers
- Preferred name
- Bromotheophylline
- IUPAC
- 8-bromo-1,3-dimethyl-7H-purine-2,6-dione
- English name
- 8-Bromotheophylline
- Molecular formula
- C7H7BrN4O2
- Molecular weight
- 259.06
Names & synonyms
Show more names
Database identifiers
- CAS
10381-75-6- PubChem CID
- 11808
- DTXSID
DTXSID7044768- UNII
- FZG87K1MQ6
- EC Number
- 233-846-6
- Nikkaji
- J236.804H
Properties
Computed structural properties
- XLogP
- 1
- Topological polar surface area
- 69.3 Ų
- Hydrogen bond donors
- 1
- Hydrogen bond acceptors
- 3
- Rotatable bonds
- 0
- Heavy atoms
- 14
- Formal charge
- 0
- Complexity
- 297
Experimental & physicochemical properties
Physicochemical properties
- Melting point
- 295 · 295-297°C
- Boiling point
- 469.5 · 469.5±55.0 °C(Predicted)
- Density
- 1.862 · 1.862±0.06 g/cm3(Predicted)
- storage temp.
- Keep in dark place,Inert atmosphere,Room temperature
- solubility
- DMSO (Slightly), Methanol (Slightly, Heated)
- pka
- 5.45 · pKa 5.45±0.1(H2O t=24) (Uncertain)
- form
- Solid
- color
- White to Off-White
- BRN
- 203069 · 203069
- CAS DataBase Reference
- 10381 · 10381-75-6
- FDA UNII
- 87 K1MQ6 · FZG87K1MQ6
- EPA Substance Registry System
- 1 H-Purine-2,6-dione, · 1H-Purine-2,6-dione, 8-bromo-3,7-dihydro-1,3-dimethyl- (10381-75-6)
- Symbol(GHS)
- 7 · GHS07
- Signal word
- Warning
- Hazard statements
- 302 · H302-H315-H319-H335
- Precautionary statements
- 261 · P261-P264-P270-P271-P280-P301+P312+P330-P302+P352-P304+P340+P312-P305+P351+P338-P332+P313-P337+P313-P362-P403+P233-P405-P501
- Risk Statements
- 20 · 20/21/22
- Safety Statements
- 24 · 24/25-36/37
- RIDADR
- 2811 · 2811
- TSCA
- TSCA listed
- HazardClass
- 6.1 · 6.1(b)
- PackingGroup
- III
- HS Code
- 29395900 · 29395900
Safety & regulation
GHS classification
GHS Classification
Warning
H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral];H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation];H319 (100%): Causes serious eye irritation [Warning Serious eye damage/eye irritation];H335 (100%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure; Respiratory tract irritation]
P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)
The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.
Hazard information
Safety data
- tsca
- TSCA listed
- ridadr
- 2811
- hs_code
- 29395900
- risk_code
- 20/21/22
- Signal word
- Warning
- Symbol(GHS)
- GHS07
- safety_code
- 24/25-36/37
- hazard_class
- 6.1(b)
- packing_group
- III
- Hazard statements
- H302-H315-H319-H335
- Precautionary statements
- P261-P264-P270-P271-P280-P301+P312+P330-P302+P352-P304+P340+P312-P305+P351+P338-P332+P313-P337+P313-P362-P403+P233-P405-P501
Chemistry & industry
Pharmacology
Pharmacodynamics
Bromotheophylline diuretic action will produce an immediate increase in urination frequency. This effect aids in the relief of bloating and menstrual pain. This diuretic function is performed by the an increase in glomerular filtration and a potential effect in the tubular reabsorption as it is established that the administration of these agents produce a rise in the urinary concentration of sodium a chloride and thus, an increase in their rates of excretion.
Mechanism of Action
Bromotheophylline is part of the group of the xanthines. As part of this group, it is thought that bromotheophylline increases the permeability of the renal tubule, increases glomerular filtration rate and inhibits the sodium reabsorption in the proximal tubule. It is thought but not confirmed that pamabrom as a mixture seems to have an additional mechanism of action in which the presence of 2-amino-2-methyl-1-propanol produces the suppression of the antidiuretic hormone in the posterior pituitary gland.
Absorption, Distribution and Excretion
When administered after one single oral dosage, bromotheophylline is rapidly absorbed and it reaches a maximal plasma concentration of 2.5 mg/L in 0.78 hours. The mean residence time is registered to be of 12 hours with an AUC in the first 8 hours of 27 mg.h/L.
This pharmacokinetic property has not been determined.
This pharmacokinetic property has not been determined.
This pharmacokinetic property has not been determined.
Uses & manufacturing
Applications
DescriptionBromotheophylline is the active moiety of pamabrom, a mixture of 2-amino-2-methyl-propanol and bromotheophylline. From this mixture, bromotheophylline acts as a weak diuretic that has been used along with some analgesics to relieve the symptoms of premenstrual syndrome. Bromotheophylline is categorized on the FDA as a drug substance with an inactive state since March, 1980. It is also approved by Health Canada to be used alone or in combination with [DB00316] in OTC products.
UsesThe active component in the diuretic Diurex.
Upstream & downstream products
Upstream raw materials
Downstream products
Suppliers84 total
Related reactions
Compound notes
Loading…